Memory disorder

How your vision can predict dementia 12 years before it is diagnosed – new study

Retrieved on: 
Wednesday, April 10, 2024
Diagnosis, Health, Eye, Attention, Brain, Memory disorder, Dementia, Face, Environment, Memory, Loughborough University, Risk, Education, Research, Amnesia, Accident, Mouth, Nose, Vision

Our latest study shows that a loss of visual sensitivity can predict dementia 12 years before it is diagnosed.

Key Points: 
  • Our latest study shows that a loss of visual sensitivity can predict dementia 12 years before it is diagnosed.
  • Our research was based on 8,623 healthy people in Norfolk, England, who were followed up for many years.
  • By the end of the study, 537 participants had developed dementia, so we could see what factors might have preceded this diagnosis.
  • People who would develop dementia were much slower to see this triangle on the screen than people who would remain without dementia.

Recognising faces

  • We have some evidence which suggests that people with dementia tend to process new people’s faces inefficiently.
  • In other words, they don’t follow the usual pattern of scanning the face of the person they are talking to.
  • So this early issue in not recognising people you have just met could be related to ineffective eye movement for new faces, rather than being a pure memory disorder.

Can eye movement improve memory?

  • Previous research on the matter is mixed, but some studies found that eye movement can improve memory.
  • In other studies, eye movements from left to right and right to left done quickly (two eye movements per second) were found to improve autobiographical memory (your life story).
  • Also, using deficits in eye movements as a diagnostic is not a regular feature, despite the possibilities in eye movement technology.


Eef Hogervorst receives funding from the Dunhill Medical Trust [email protected] receives funding from Road Safety Trust. He is affiliated with Applied Vision Association. Ahmet Begde does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Neurologists React to CMS' Proposed NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease in the Latest from Spherix Global Insights

Retrieved on: 
Thursday, January 27, 2022
Awareness, MCI, Decision-making, Lilly, Patient, Centers for Medicare & Medicaid Services, Neutralizing antibody, Neurology, Center, Donanemab, FDA, CMS, CED, US, Research, Amyloid, NCD, Memory disorder, NIH, Randomized controlled trial, Medicare, Eli Lilly and Company, National coverage determination, Safety, Disease, Pharmaceutical industry, Medical imaging, Risk management, Alzheimer's disease

Days later, Spherix surveyed 75 U.S. neurologists and Alzheimer's disease specialists (including five follow-up interviews) to evaluate their awareness of and opinions on this unprecedented event.

Key Points: 
  • Days later, Spherix surveyed 75 U.S. neurologists and Alzheimer's disease specialists (including five follow-up interviews) to evaluate their awareness of and opinions on this unprecedented event.
  • The resulting insights are part of a two-wave Special Topix: Impact of CMS Reimbursement Decision on Alzheimer's Disease Therapies service.
  • However, respondents show lack of consensus on whether the NCD should include not-yet-approved anti-amyloid mAbs (i.e., Eli Lilly's donanemab, Eisai/Biogen's lecanemab, and Roche/Genentech's gantenerumab).
  • The waves of research will field immediately following the releases of the draft and final NCD decisions.

uMETHOD Health Announces the Release of a Revolutionary Methodology to Help Prevent Alzheimer's Disease and Cognitive Decline

Retrieved on: 
Thursday, June 18, 2020
RTT, Psychiatric diagnosis, Psychiatry, Cognitive disorders, Learning disabilities, Branches of biology, Neuroscience, Dementia, Alzheimer's disease, Neurogenomics, Memory disorder

The ExtND METHOD enables doctors to have a straightforward way to practice and prevent brain decline, by providing personalized plans tailored to each individual.

Key Points: 
  • The ExtND METHOD enables doctors to have a straightforward way to practice and prevent brain decline, by providing personalized plans tailored to each individual.
  • The biological progression of Alzheimer's disease tends to start in the brain 10 to 20 years before the onset of symptoms.
  • Each person has unique genetics and their own unique set of health factors that drive cognitive decline.
  • "Personalized methodologies, such as those developed by uMETHOD Health, are the future for prevention and treatment of complex neurological disorders.

Early-Onset Dementia and Alzheimer's Diagnoses Spiked 373 Percent for Generation X and Millennials

Retrieved on: 
Thursday, February 27, 2020
Psychiatric diagnosis, Psychiatry, Cognitive disorders, Learning disabilities, RTT, Health, Dementia, Neuroscience, Alzheimer's disease, Geriatric psychology, Memory disorder

The average age of a person living with either form of dementia is 49.

Key Points: 
  • The average age of a person living with either form of dementia is 49.
  • These conditions are more common in women, who make up 58% of those diagnosed.
  • "Further education and research is needed to learn more about early-onset dementia and Alzheimer's, how to treat these conditions and what can be done to better prevent diagnoses."
  • An increase in Alzheimer's diagnoses among younger generations can lead to even greater economic consequences and mental stress for those that provide them care.